Topic

Head of Pharmacovigilance and Regulatory Technology, IQVIA

Articles

Automated risk management and improved regulatory compliance among opportunities offered by case collection.

The Benefits of Enhancing Adverse Event Intake With Case Collection Systems

Addressing sources of tension on differentiating types of data.

Just How ‘Real’ is Real-World Data?

Recent advances from COVID-19 vaccine development put pharma in place to further grow relationship with patients.

Patients Are Ready for a Digital Future, Here’s Pharma’s Path Toward the Next Growth Horizon

's Online and European Editor. He can be reached at jupton@mjhlifesciences.com

With more promising products emerging, investment risks remain.

Assessing the Growth of Digital Therapeutics: Latest News and Views

Hill shares her insights on what is needed for a turnaround in talent development.

Q&A With Harvard Business School Professor Linda A. Hill

Despite the rapid innovation of machine learning, correct protocols to ensure compliance and trustworthiness must be considered.

Why Machine Learning's Potential in Pharma Relies on Its Transparency

From exposing disparities in care to guiding better patient outcomes to helping reign in the costs of care, the use of real-world data (RWD) in oncology can have far-reaching effects. Here’s how one RWD company exec is using her experience to help drive that change.

Q&A With Miruna Sasu, president and CEO, COTA, Inc.

Executive Director of Medical Affairs, Within3

What’s next and lasting in engagement for medical affairs and commercial teams isn’t complicated, but a big shift is here to stay, according to analysis of an industry survey.

How and Why the New ‘Over-Time’ Is Transforming the Work of Medical Affairs

Rohit Gupta is vice president of analytics strategy and transformation at 

Continued push for latest technology in biopharma will advance collection of patient data.

Web3 Promises to Unleash Health Data: What Does That Mean for Biopharma?

Genomic data is transforming precision medicine—but progress depends on it being easily available where it’s needed. Pharmaceutical Executive speaks to Ignacio Medina, founder of Cambridge University spinout Zetta Genomics, to see how next-generation open-source data technologies accelerate discovery in the lab and patient benefit in the clinic.